Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, February 01, 2015
Technology Networks
 
Register | Sign in
Home Page
  News
Return

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Cancer Genetics, Inc. announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Study Links Deficiency of Cellular Housekeeping Gene with Aggressive Forms of Breast Cancer
Research team studies genes involved in the autophagy process and their roles in cancer, aging, infections, and neurodegenerative diseases.
“Unprecedented Sensitivity and Specificity” in Ovarian Cancer
Study of the use of the Parsortix system as a clinical application in the detection and treatment of ovarian cancer patients.
Study Uncovers Range of Molecular Alterations in Head and Neck Cancers
TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smoking, and find genomic similarities with other cancers.
Cancer-Causing Virus Blocks Human Immune Response
Epstein-Barr virus shown to outwit the human immune response using microRNAs.
Major Study Links Gene to Drug Resistance in Testicular Cancer
Researchers used a genetic technique called whole-exome sequencing to examine tumour samples.
New Blood Test For Aggressive Bone Cancer
Researchers at the University of East Anglia are developing a simple blood test to diagnose bone cancer thanks to funding from the Big C.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Tumor Suppressor Protein Plays Key Role In Maintaining Immune Balance
St. Jude Children’s Research Hospital scientists show that the PTEN tumor suppressor protein is essential for proper regulatory T cell function; discovery offers new focus for improving treatment of autoimmune diseases.
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows
Statistical modeling links cancer risk with number of stem cell divisions.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn